发布求助
文献互助 智能选刊 最新文献

Im Focus Onkologie最新文献

筛选
英文 中文
Von wegen symmetrisch 通过对称的方式
Im Focus Onkologie Pub Date : 2018-11-01 DOI: 10.1007/s15015-018-4299-x
M. Borchers
{"title":"Von wegen symmetrisch","authors":"M. Borchers","doi":"10.1007/s15015-018-4299-x","DOIUrl":"https://doi.org/10.1007/s15015-018-4299-x","url":null,"abstract":"","PeriodicalId":13382,"journal":{"name":"Im Focus Onkologie","volume":"144 1","pages":"54"},"PeriodicalIF":0.0,"publicationDate":"2018-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89013757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nierenkrebs: Aktive Überwachung auch auf lange Sicht sicher 肾癌持续监控将十分安全
Im Focus Onkologie Pub Date : 2018-11-01 DOI: 10.1007/s15015-018-4282-6
Peter Leiner
{"title":"Nierenkrebs: Aktive Überwachung auch auf lange Sicht sicher","authors":"Peter Leiner","doi":"10.1007/s15015-018-4282-6","DOIUrl":"https://doi.org/10.1007/s15015-018-4282-6","url":null,"abstract":"","PeriodicalId":13382,"journal":{"name":"Im Focus Onkologie","volume":"39 1","pages":"40"},"PeriodicalIF":0.0,"publicationDate":"2018-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77428816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Multigentest hilft, Frauen mit Brustkrebs die Chemo zu ersparen 多亏了测谎后
Im Focus Onkologie Pub Date : 2018-11-01 DOI: 10.1007/s15015-018-4284-4
Peter Leiner
{"title":"Multigentest hilft, Frauen mit Brustkrebs die Chemo zu ersparen","authors":"Peter Leiner","doi":"10.1007/s15015-018-4284-4","DOIUrl":"https://doi.org/10.1007/s15015-018-4284-4","url":null,"abstract":"","PeriodicalId":13382,"journal":{"name":"Im Focus Onkologie","volume":"3 1","pages":"43"},"PeriodicalIF":0.0,"publicationDate":"2018-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91203935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
PD-1-Inhibition bei fortgeschrittenem malignem Melanom 对赞
Im Focus Onkologie Pub Date : 2018-11-01 DOI: 10.1007/s15015-018-4306-2
Beate Grübler
{"title":"PD-1-Inhibition bei fortgeschrittenem malignem Melanom","authors":"Beate Grübler","doi":"10.1007/s15015-018-4306-2","DOIUrl":"https://doi.org/10.1007/s15015-018-4306-2","url":null,"abstract":"","PeriodicalId":13382,"journal":{"name":"Im Focus Onkologie","volume":"1 1","pages":"73 - 73"},"PeriodicalIF":0.0,"publicationDate":"2018-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90564532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Eine Forderung: Zuschlag für Mehrleistungen 就是你要的福利
Im Focus Onkologie Pub Date : 2018-11-01 DOI: 10.1007/s15015-018-4304-4
Springer Medizin
{"title":"Eine Forderung: Zuschlag für Mehrleistungen","authors":"Springer Medizin","doi":"10.1007/s15015-018-4304-4","DOIUrl":"https://doi.org/10.1007/s15015-018-4304-4","url":null,"abstract":"","PeriodicalId":13382,"journal":{"name":"Im Focus Onkologie","volume":"118 1","pages":"71"},"PeriodicalIF":0.0,"publicationDate":"2018-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88073651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Krebsimmuntherapie bei urogenitalen Tumoren 泌尿肿瘤肿瘤的癌症治疗
Im Focus Onkologie Pub Date : 2018-11-01 DOI: 10.1007/s15015-018-4321-3
S. Lux
{"title":"Krebsimmuntherapie bei urogenitalen Tumoren","authors":"S. Lux","doi":"10.1007/s15015-018-4321-3","DOIUrl":"https://doi.org/10.1007/s15015-018-4321-3","url":null,"abstract":"","PeriodicalId":13382,"journal":{"name":"Im Focus Onkologie","volume":"37 1","pages":"77 - 77"},"PeriodicalIF":0.0,"publicationDate":"2018-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86632602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Neue Therapieoptionen beim Lungenkarzinom 肺结核的新疗法
Im Focus Onkologie Pub Date : 2018-11-01 DOI: 10.1007/s15015-018-4266-6
Diana S.Y. Abdulla, C. Heydt, J. Wolf
{"title":"Neue Therapieoptionen beim Lungenkarzinom","authors":"Diana S.Y. Abdulla, C. Heydt, J. Wolf","doi":"10.1007/s15015-018-4266-6","DOIUrl":"https://doi.org/10.1007/s15015-018-4266-6","url":null,"abstract":"","PeriodicalId":13382,"journal":{"name":"Im Focus Onkologie","volume":"22 1","pages":"18-24"},"PeriodicalIF":0.0,"publicationDate":"2018-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84684176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Zervixkarzinom im Stadium IIIb: Vorteil durch Radiochemotherapie bestätigt 第三阶段癌症放射化学治疗确认其好处
Im Focus Onkologie Pub Date : 2018-11-01 DOI: 10.1007/s15015-018-4283-5
N. Gharbi, S. Kunze, J. Herter, S. Marnitz-Schulze
{"title":"Zervixkarzinom im Stadium IIIb: Vorteil durch Radiochemotherapie bestätigt","authors":"N. Gharbi, S. Kunze, J. Herter, S. Marnitz-Schulze","doi":"10.1007/s15015-018-4283-5","DOIUrl":"https://doi.org/10.1007/s15015-018-4283-5","url":null,"abstract":"","PeriodicalId":13382,"journal":{"name":"Im Focus Onkologie","volume":"25 1","pages":"41-43"},"PeriodicalIF":0.0,"publicationDate":"2018-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91015375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Biosimilar CT-P10 gleichwertige Alternative zu Rituximab 生物仿制药CT-P10 gleichwertige Alternative zu Rituximab
Im Focus Onkologie Pub Date : 2018-11-01 DOI: 10.1007/s15015-018-4320-4
A. Warpakowski
{"title":"Biosimilar CT-P10 gleichwertige Alternative zu Rituximab","authors":"A. Warpakowski","doi":"10.1007/s15015-018-4320-4","DOIUrl":"https://doi.org/10.1007/s15015-018-4320-4","url":null,"abstract":"","PeriodicalId":13382,"journal":{"name":"Im Focus Onkologie","volume":"111 1","pages":"77 - 77"},"PeriodicalIF":0.0,"publicationDate":"2018-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79284814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
NHL: Länger progressionsfrei überleben mit Typ-II-CD20-Antikörper 老年痴呆症还活着
Im Focus Onkologie Pub Date : 2018-11-01 DOI: 10.1007/s15015-018-4293-3
P. Risch
{"title":"NHL: Länger progressionsfrei überleben mit Typ-II-CD20-Antikörper","authors":"P. Risch","doi":"10.1007/s15015-018-4293-3","DOIUrl":"https://doi.org/10.1007/s15015-018-4293-3","url":null,"abstract":"","PeriodicalId":13382,"journal":{"name":"Im Focus Onkologie","volume":"36 1","pages":"50"},"PeriodicalIF":0.0,"publicationDate":"2018-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78399364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信